LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma

Photo from wikipedia

Rachna T Shroff, Mark Yarchoan, Ashley O’Connor, Denise Gallagher, Marianna L Zahurak, Gary Rosner, Chimela Ohaji, Susan Sartorius-Mergenthaler, Rose Parkinson, Vivek Subbiah, Ralph Zinner and Nilofer S Azad The University… Click to show full abstract

Rachna T Shroff, Mark Yarchoan, Ashley O’Connor, Denise Gallagher, Marianna L Zahurak, Gary Rosner, Chimela Ohaji, Susan Sartorius-Mergenthaler, Rose Parkinson, Vivek Subbiah, Ralph Zinner and Nilofer S Azad The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard Unit 426, Houston, TX 77030, USA; Gastrointestinal Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, Room 4M10, Baltimore, MD 21287, USA and The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, Room 4M10, Baltimore, MD 21287, USA

Keywords: inhibitor; vegf receptor; receptor tyrosine; cancer center; cancer; oral vegf

Journal Title: British Journal of Cancer
Year Published: 2018

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.